Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Tarix Pharmaceuticals has recruited first patient in a Phase 1 trial to investigate the safety and efficacy of TXA127 after double cord blood stem cell transplant (DCBT) in adult patients with hematological cancers.
Subscribe to our email newsletter
TXA127 is a pharmaceutical grade formulation of a naturally occurring peptide known to stimulate early hematopoietic precursor cells in the bone marrow.
The company will compare the time to engraftment for patients receiving TXA127 to that of historical controls in order to investigate the efficacy of TXA127 in speeding up the engraftment process.
Tarix Pharma CEO Rick Franklin said initiation of the Phase 1 clinical program in DCBT marks another significant milestone in the development of TXA127 for enhancing engraftment following stem cell transplantation.
"We are excited to advance these programs in order to address the unmet needs of the full spectrum of patients undergoing hematopoietic stem cell transplants," Franklin said.
TXA127 was granted orphan drug designation from the US Food and Drug Administration as a treatment to enhance engraftment in patients receiving a stem cell transplant and as a treatment of Myelodysplastic Syndrome (MDS).